Mabqi & Abzena established a partnership to integrate Mabqi’s antibody discovery capabilities with Abzena’s development and manufacturing services, offering biopharma customers a more streamlined, end-to-end drug development solution.
The partnership’s combined offerings will leverage Mabqi’s LiteMab© Antibody Discovery Studio for hit screening, characterization, and hit selection by using universal & pH-sensitive libraries to identify top lead candidates, and take advantage of Abzena’s capabilities for developability, cell line development, process development, and GMP manufacturing.
For more information read the press release.
